Cargando…

Evaluating Post-Market Adverse Events of The New Hepatitis C Therapies Using FEARS Data

Background: Little is known regarding the safety of direct-acting antivirals (DAA), even though they are widely used. This study aims to evaluate the adverse events of DAA using post-market data. Methods: FDA Adverse Events Reporting System (FAERS) data from January 2019 through December 2019 were a...

Descripción completa

Detalles Bibliográficos
Autor principal:	Algarni, Majed A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408496/ https://www.ncbi.nlm.nih.gov/pubmed/36011057 http://dx.doi.org/10.3390/healthcare10081400

Ejemplares similares

Comparing drug safety of hepatitis C therapies using post-market data
por: Huang, Jing, et al.
Publicado: (2019)

2489. Adverse Events with Biktarvy: Post-Marketing Study
por: Hayes, Edwin, et al.
Publicado: (2019)

Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance
por: Wakabayashi, Tomohito, et al.
Publicado: (2022)

Predicting potential adverse events using safety data from marketed drugs
por: Daluwatte, Chathuri, et al.
Publicado: (2020)

Large-scale mining disease comorbidity relationships from post-market drug adverse events surveillance data
por: Zheng, Chunlei, et al.
Publicado: (2018)

Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy)
por: Stefanizzi, Pasquale, et al.
Publicado: (2023)

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

Adverse Events of Vaccination against Hepatitis B Virus in Post-Marketing Surveillance from 2005 to 2017 in Guangdong Province, China
por: Liu, Yu, et al.
Publicado: (2022)

Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System
por: Mina, Syeda A., et al.
Publicado: (2021)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
por: Soldatos, Theodoros G., et al.
Publicado: (2022)

When vaccine adverse event reporting generates hope, not fear
por: Chang, Joyce C, et al.
Publicado: (2022)

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market
por: Gastaldon, C., et al.
Publicado: (2021)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

The fearful rise of synchronized markets
por: Authers, John, et al.
Publicado: (2011)

Fear of the coronavirus and the stock markets
por: Lyócsa, Štefan, et al.
Publicado: (2020)

Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection
por: Pawlowska, Malgorzata, et al.
Publicado: (2011)

A Pharmacovigilance Approach for Post-Marketing in Japan Using the Japanese Adverse Drug Event Report (JADER) Database and Association Analysis
por: Fujiwara, Masakazu, et al.
Publicado: (2016)

Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports
por: Ekhart, Corine, et al.
Publicado: (2022)

Safety of Sublingual Immunotherapy: A Secondary Analysis of Post-marketing Adverse Events Reports Using a Japanese Public Database
por: Kaneda, Yudai, et al.
Publicado: (2023)

Inflation Fears and Strong Labor Markets
por: Baker, Dean
Publicado: (2022)

Reporting of adverse events for marketed drugs: Need for strengthening safety database
por: Apte, Aditi Anand
Publicado: (2016)

Sustained Viral Response and Hematological Adverse Events in Children With Chronic Hepatitis C
por: Vigano, Alessandra, et al.
Publicado: (2012)

Management of Hepatitis C Antiviral Therapy Adverse Effects
por: Sung, Hubert, et al.
Publicado: (2010)

Comparison of the post-marketing safety profile between influenza and COVID-19 vaccines: An analysis of the vaccine adverse event reporting system
por: Al-Ahmari, Abdullah K., et al.
Publicado: (2022)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
por: Jiang, Tingting, et al.
Publicado: (2022)

Adverse events and technical complaints related to central venous catheters marketed in Brazil
por: Morais, Luciene de Oliveira, et al.
Publicado: (2013)

Adverse Events in NMOSD Therapy
por: Giglhuber, Katrin, et al.
Publicado: (2022)

Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
por: Elsayed, Amr, et al.
Publicado: (2020)

Evaluating adverse events in databases
por: Lovell, Katie, et al.
Publicado: (2023)

Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016
por: Mentzer, Dirk, et al.
Publicado: (2018)

Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance
por: Mariottini, Alice, et al.
Publicado: (2022)

Data-driven Markov models and their application in the evaluation of adverse events in radiotherapy
por: Abler, Daniel, et al.
Publicado: (2013)

Data-driven Markov models and their application in the evaluation of adverse events in radiotherapy
por: Abler, Daniel, et al.
Publicado: (2013)

Antibacterial‐associated acute kidney injury among older adults: A post‐marketing surveillance study using the FDA adverse events reporting system
por: Chinzowu, Tichawona, et al.
Publicado: (2022)

Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database
por: Altebainawi, Ali F., et al.
Publicado: (2023)

New approach to decrease post-ERCP adverse events in patients with primary sclerosing cholangitis
por: Navaneethan, Udayakumar, et al.
Publicado: (2017)

Sustained Viral Response and Hematological Adverse Events During Chronic Hepatitis C Infection Treatment
por: El-Shabrawi, Mortada, et al.
Publicado: (2012)

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
por: Teixeira, Rosângela, et al.
Publicado: (2013)

Rivaroxaban Rebound Acute Coronary Event: A Post Marketing Experience
por: Agarwal, Ajay, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_10b57lm6e894lrj1ndaske3s82